Novel therapies for patients with vision disorders
Our Vision
To create globally disruptive, non-surgical treatments for patients with vision disorders.
To that end, we are developing a unique therapy which will induce therapeutic remodeling of the cornea in patients with ectatic disorders such as keratoconus.
Keratoconus
A progressive disorder, keratoconus results in gradual thinning and weakening of the cornea, resulting in it becoming conically shaped. This severely impairs vision, which in some cases can worsen at a rapid rate.
Current therapeutic strategies focus on addressing vision impairments via glasses and corrective lenses, or on halting progression of the disease via the corneal cross-linking procedure, but there is no cure for this disease.
Our Company
TheiaNova builds upon work done by Professors Colin Green and Trevor Sherwin, Associate Professor Ilva Rupenthal, and Dr. Carol Greene in the Department of Ophthalmology at the University of Auckland.
Our goal now is to bring this therapy into the clinic so that patients will be able to benefit from it as soon as possible.
By committing to our values of integrity, inclusivity, and agility we aim to generate sound evidence to support our therapy, to take into account the needs of our patients and their physicians as well as our internal and external stakeholders and advisors, and to find ways to shorten the route from bench to bedside as much as reasonably possible.
Our Partnerships
TheiaNova is proudly supported by Bridgewest Ventures NZ LP. Bridgewest Ventures is part of the Bridgewest Group and has a long track record of successfully incubating and launching major global innovation-led companies. Bridgewest’s deep technology experience is wide-ranging and includes drug discovery and deep research into health technology. Bridgewest Ventures leverage their extensive connections, international reach, and commercialisation experience to transform innovative opportunities into world-class companies.
The commercialization of TheiaNova’s therapeutic agent has been fostered and continues to be proudly supported by UniServices, the research application company of Waipapa Taumata Rau, University of Auckland.
UniServices advances and invests in the ideas and intellectual property that arise from the University by helping translate it into products, services, companies and public-good projects, all to build a better world.
We are proud to be part of Callaghan Innovation’s Technology Incubator Programme.
Callaghan Innovation is New Zealand’s innovation agency. It activates innovation and helps businesses grow faster for a better New Zealand. The government agency delivers a range of innovation and R&D services to suit each stage of business growth.
Its staff – including more than 200 of New Zealand’s leading scientists and engineers – empower innovators by connecting people, opportunities, and networks and providing tailored technical solutions, skills and capability development programmes, and grants co-funding.
Our Memberships
Get in touch
We’d love to hear from you.